Loading
Kailera Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RTW INVESTMENTS, LP, was filed 22 Apr 2026.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€142M
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBain Capital Investors LLC1 buy
Bain Capital Life Sciences Investors, LLC1 buy
RTW Investments, LP1 buy
Since the insiders bought
- -48.6%Entry US$25.08 · Close 21 Oct 2026 US$12.90
- -48.9%Entry US$25.22 · Close 21 Oct 2026 US$12.90
- -48.9%Entry US$25.22 · Close 21 Oct 2026 US$12.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kailera Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$42.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.43
Analyst consensus
5 analystsStrong buy
US$30.00Target US$42.40(+271%)US$57.00
Income statement
EBITDA-US$158M
Net income-US$149M0.0% margin
Valuation
PER (forward)-2.7x
P/Book1.3x
Balance sheet & cash
Market capUS$1.5B
Total debtUS$10.8M
Free Cash Flow-US$122.3M
Debt / Equity1%
Profitability & ownership
% insiders8.9%
% institutions90.4%
Last declaration on 22 April 2026
Declarations14 total
500,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001231919-26-000390:1
Canonical exit: 19 Jul 2026 (T+90)
9,477,719 sharesCommon StockSEC:0001104659-26-046276:0
2,034,133 sharesCommon StockSEC:0001104659-26-046276:1
10,276,820 sharesCommon StockSEC:0001231919-26-000390:0
8,398,438 shares@ US$16.00100.0% of flowCommon StockSEC:0001193125-26-164417:1
Canonical exit: 19 Jul 2026 (T+90)
1,562,500 shares@ US$16.00100.0% of flowCommon StockSEC:0001193125-26-164389:2
Canonical exit: 19 Jul 2026 (T+90)
17,857,143 sharesCommon StockSEC:0001193125-26-164417:0
16,875,000 sharesCommon StockSEC:0001193125-26-164389:0
4,145,768 sharesCommon StockSEC:0001193125-26-164389:1
17,857,143 sharesCommon StockSEC:0001193125-26-164388:0
16,875,000 sharesCommon StockSEC:0001193125-26-164407:0
4,145,768 sharesCommon StockSEC:0001193125-26-164407:1
8,398,438 shares@ US$16.00100.0% of flowCommon StockSEC:0001193125-26-164388:1
Canonical exit: 19 Jul 2026 (T+90)
▲
Same trade as the filing by Bain Capital Life Sciences Investors, LLC, counted once
25M USD37SEC
1,562,500 shares@ US$16.00100.0% of flowCommon StockSEC:0001193125-26-164407:2
Canonical exit: 19 Jul 2026 (T+90)
14 of 14 declarations
About Kailera Therapeutics, Inc.
The whole record at Kailera Therapeutics, Inc. fits in one day: on April 20, 2026, 3 holders of more than 10% bought for EUR 142,031,086. Bain Capital Investors LLC took EUR 114,027,946, Bain Capital Life Sciences Investors, LLC EUR 21,214,500, and RTW Investments, LP EUR 6,788,640. These 3 open-market purchases, with a median of EUR 21,214,500, are the only market trades. No sale is recorded.
The 12 filings were published from April 20, 2026 to April 22, 2026. Nine are of a nature other than purchase or sale. Bain Capital Life Sciences Investors, RTW Investments and Bain Capital Investors LLC have 3, 2 and 2 filings respectively, with one purchase each. Jiangsu Hengrui Pharmaceuticals Co., Ltd., another holder of more than 10%, has 2, with no purchase, and Adam Koppel (Director) 2.
Read moreShow less
The US health care company is valued at USD 1.48 billion, and 8.9% of its capital is held by insiders. 6 filers appear in the record, and filings are published on the day of the trade, as a median.
